Feltsense | $5,100,000 | (Feb 5, 2026)
Stratus Medical | $10,000,000 | (Feb 5, 2026)
beHuman Corp. | $4,000,000 | (Feb 5, 2026)
Sudo Biosciences
United States
- Menlo Park, California
- 21/12/2023
- Series B
- $116,000,000
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
- Industry Biotechnology Research
- Website https://www.sudobio.com/
- LinkedIn https://www.linkedin.com/company/sudo-biosciences/
Related People
Scott ByrdFounder
United States -
Zionsville, Indiana
Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.
Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.
Boomband | $4,000,000 | (Feb 5, 2026)
Bedrock Robotics | $270,000,000 | (Feb 5, 2026)
Fibr AI | $7,500,000 | (Feb 5, 2026)
Expert Intelligence™ | $4,700,000 | (Feb 5, 2026)
Positron AI | $230,000,000 | (Feb 5, 2026)
Chamber(US) | $60,000,000 | (Feb 5, 2026)
SENAI | $6,200,000 | (Feb 5, 2026)
OneDome | $25,000,000 | (Feb 4, 2026)
Naoma AI | $440,000 | (Feb 4, 2026)